SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cambridge Antibody Technology Group
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: nigel bates who wrote (364)6/4/2003 5:14:02 PM
From: keokalani'nui  Read Replies (1) of 625
 
>>If Abbott's claims are upheld, then royalty payments could slip to around 1.5% of revenue from around 4%.<<

If this is true, I would really like to know who has scared ABT into thinking it is to be paid around 2.5% of H. That is a sweet little annuity. Can't be Dyax, could it be Dyax? Someone on the Q&A mentioned something about ABT disclosing who--a feint I think to get CAT's lips moving.

By the way, there is a cute little chart on the ABT R&D webcast showing newly announced Crohn's data. Not much info on endpoints, definition of responders...but a pretty picture anyway.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News